← Back to Search

Nonsteroidal Anti-inflammatory Drug (NSAID)

Diacerein for Osteoarthritis (DISSCO Trial)

Phase 3

Waitlist Available

Led By Jean-Pierre Pelletier, MD, FRCPC

Research Sponsored by TRB Chemedica International SA

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 728 days

Awards & highlights

All Individual Drugs Already Approved

Approved for 10 Other Conditions

Pivotal Trial

Summary

This trial compares Diacerein and Celecoxib in patients aged 50 and older with knee osteoarthritis. Diacerein helps protect cartilage by blocking harmful substances, while Celecoxib reduces pain and inflammation. The study aims to determine which medication is more effective at reducing symptoms and preventing structural damage. Diacerein has been studied for its efficacy in reducing pain in knee osteoarthritis patients, with a focus on its cartilage-protective properties.

Eligible Conditions

Osteoarthritis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 728 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 728 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 728 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change Form Baseline in WOMAC A Pain Subscale

Secondary study objectives

Absolute Changes From Baseline in Pain Visual Analogue Scale

Assessment of Joint Swelling, Effusion or Both

Change From Baseline in Patient's Global Assessment of Disease Activity

+5 more

Other study objectives

Cartilage Volume Loss From Baseline in the Lateral Compartment Using MRI

Cartilage Volume Loss From Baseline in the Medial Compartment Using MRI

Change From Baseline in Global Stiffness Using WOMAC Subscale

+3 more

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Approved for 10 Other Conditions

This treatment demonstrated efficacy for 10 other conditions.

Pivotal Trial

The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: DiacereinExperimental Treatment2 Interventions

One placebo capsule once daily in the morning (breakfast) and one diacerein 50 mg capsule once daily in the evening (dinner) for the first month, then diacerein capsules twice daily with meals in the morning (breakfast) and the evening (dinner).

Group II: CelecoxibActive Control2 Interventions

One celecoxib 200 mg capsule once daily in the morning (breakfast) and one placebo capsule once daily in the evening (dinner).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo

1995

Completed Phase 3

~2670

Diacerein

FDA approved